

Paper alert

83 **Martin Read & Robert E Hurst**

Patent alert

87 **Emine Abali & Tatiana Litvin-Vechnyak**

Web alert

89 **Alick C Stephens**

Oligonucleotide, antibody and peptide therapeutics – from design to the clinic

Edited by John Goodchild & Patrick L Iversen

- 91 **John Goodchild**
Editorial overview: Oligonucleotide, antibody and peptide therapeutics
- 93 **Kelly L Warfield, Rekha G Panchal, M Javad Aman & Sina Bavari**
Antisense treatments for biothreat agents
- 104 **Travis W Lim, Ji Yuan, Zhen Liu, Dexin Qiu, Alhousseynou Sall & Decheng Yang**
Nucleic-acid-based antiviral agents against positive single-stranded RNA viruses
- 108 **Martin M Fabani, John J Turner & Michael J Gait**
Oligonucleotide analogs as antiviral agents
- 115 **Kevin V Morris & John J Rossi**
Antiviral applications of RNAi
- 122 **Kristian CD Becker & Richard C Becker**
Nucleic acid aptamers as adjuncts to vaccine development
- 130 **Steve D Wilton & Susan Fletcher**
Modification of pre-mRNA processing: Application to dystrophin expression
- 136 **Donald J Hnatowich & Kayoko Nakamura**
The influence of chemical structure of DNA and other oligomer radiopharmaceuticals on tumor delivery
- 144 **Makoto Koizumi**
ENA[®] oligonucleotides as therapeutics
- 150 **Joseph Jao-Yiu Sung & Henry Lik-Yuen Chan**
Technology evaluation: HBV-ISS, Dynavax
- 156 **Philippe Taupin**
Technology evaluation: HuCNS-SC, StemCells
- 164 **Roland Schnell & Peter Borchmann**
Technology evaluation: SGN-30, Seattle Genetics